PE20150629A1 - Derivados de etinilo como moduladores de la actividad del receptor de mglur5 - Google Patents
Derivados de etinilo como moduladores de la actividad del receptor de mglur5Info
- Publication number
- PE20150629A1 PE20150629A1 PE2015000396A PE2015000396A PE20150629A1 PE 20150629 A1 PE20150629 A1 PE 20150629A1 PE 2015000396 A PE2015000396 A PE 2015000396A PE 2015000396 A PE2015000396 A PE 2015000396A PE 20150629 A1 PE20150629 A1 PE 20150629A1
- Authority
- PE
- Peru
- Prior art keywords
- disease
- modulators
- receptor activity
- phenyletinyl
- methanone
- Prior art date
Links
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229940126662 negative allosteric modulator Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188940 | 2012-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150629A1 true PE20150629A1 (es) | 2015-05-11 |
Family
ID=47049067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000396A PE20150629A1 (es) | 2012-10-18 | 2013-10-15 | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9227959B2 (OSRAM) |
| EP (1) | EP2909180B1 (OSRAM) |
| JP (1) | JP5989250B2 (OSRAM) |
| KR (1) | KR101684816B1 (OSRAM) |
| CN (1) | CN104718192B (OSRAM) |
| AR (1) | AR093042A1 (OSRAM) |
| AU (1) | AU2013333988B2 (OSRAM) |
| BR (1) | BR112015006454A8 (OSRAM) |
| CA (1) | CA2882520A1 (OSRAM) |
| CL (1) | CL2015000891A1 (OSRAM) |
| CO (1) | CO7200248A2 (OSRAM) |
| CR (1) | CR20150144A (OSRAM) |
| EA (1) | EA025667B1 (OSRAM) |
| ES (1) | ES2599553T3 (OSRAM) |
| IL (1) | IL237380A (OSRAM) |
| MA (1) | MA38012B1 (OSRAM) |
| MX (1) | MX2015004898A (OSRAM) |
| MY (1) | MY168937A (OSRAM) |
| NZ (1) | NZ705144A (OSRAM) |
| PE (1) | PE20150629A1 (OSRAM) |
| PH (1) | PH12015500398B1 (OSRAM) |
| SG (1) | SG11201501392TA (OSRAM) |
| TW (1) | TWI490208B (OSRAM) |
| UA (1) | UA114529C2 (OSRAM) |
| WO (1) | WO2014060398A1 (OSRAM) |
| ZA (1) | ZA201500856B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150070102A (ko) * | 2012-10-18 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | mGluR5 수용체 활성의 조절제로서 에틴일 유도체 |
| DK3303316T3 (da) | 2015-06-03 | 2020-04-27 | Hoffmann La Roche | Ethynylderivater |
| WO2017053769A1 (en) * | 2015-09-25 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Triazole derivatives as p2y14 receptor antagonists |
| BR112020008583A2 (pt) | 2017-12-08 | 2020-10-20 | Boehringer Ingelheim International Gmbh | derivados de imidazopiridina e uso dos mesmos como medicamento |
| WO2020079040A1 (en) * | 2018-10-17 | 2020-04-23 | Boehringer Ingelheim International Gmbh | 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament |
| ES2940184T3 (es) | 2018-10-17 | 2023-05-04 | Boehringer Ingelheim Int | Derivados de 4-pirazin-2-ilmetil-morfolina y uso de los mismos como medicamento |
| TW202035396A (zh) | 2018-10-17 | 2020-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 4-吡啶基甲基-嗎啉衍生物及其作為藥物之用途 |
| EP3980401A1 (en) | 2019-06-04 | 2022-04-13 | Boehringer Ingelheim International GmbH | Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders |
| US12398143B2 (en) | 2019-06-04 | 2025-08-26 | Boehringer Ingelheim International Gmbh | Imidazopyrazine derivatives and the use thereof as medicament |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| MX2009013169A (es) * | 2007-06-03 | 2010-04-30 | Univ Vanderbilt | Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos. |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| WO2013049255A1 (en) * | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
-
2013
- 2013-10-15 UA UAA201504680A patent/UA114529C2/uk unknown
- 2013-10-15 JP JP2015535066A patent/JP5989250B2/ja not_active Expired - Fee Related
- 2013-10-15 EA EA201590699A patent/EA025667B1/ru not_active IP Right Cessation
- 2013-10-15 AU AU2013333988A patent/AU2013333988B2/en not_active Ceased
- 2013-10-15 WO PCT/EP2013/071500 patent/WO2014060398A1/en not_active Ceased
- 2013-10-15 CA CA2882520A patent/CA2882520A1/en not_active Abandoned
- 2013-10-15 SG SG11201501392TA patent/SG11201501392TA/en unknown
- 2013-10-15 NZ NZ705144A patent/NZ705144A/en not_active IP Right Cessation
- 2013-10-15 CN CN201380053660.XA patent/CN104718192B/zh not_active Expired - Fee Related
- 2013-10-15 MX MX2015004898A patent/MX2015004898A/es unknown
- 2013-10-15 KR KR1020157009544A patent/KR101684816B1/ko not_active Expired - Fee Related
- 2013-10-15 ES ES13783003.0T patent/ES2599553T3/es active Active
- 2013-10-15 MY MYPI2015000470A patent/MY168937A/en unknown
- 2013-10-15 PE PE2015000396A patent/PE20150629A1/es active IP Right Grant
- 2013-10-15 BR BR112015006454A patent/BR112015006454A8/pt not_active Application Discontinuation
- 2013-10-15 EP EP13783003.0A patent/EP2909180B1/en active Active
- 2013-10-17 TW TW102137560A patent/TWI490208B/zh not_active IP Right Cessation
- 2013-10-17 AR ARP130103764A patent/AR093042A1/es unknown
-
2015
- 2015-02-05 ZA ZA2015/00856A patent/ZA201500856B/en unknown
- 2015-02-16 CO CO15032736A patent/CO7200248A2/es unknown
- 2015-02-23 IL IL237380A patent/IL237380A/en not_active IP Right Cessation
- 2015-02-24 PH PH12015500398A patent/PH12015500398B1/en unknown
- 2015-03-18 CR CR20150144A patent/CR20150144A/es unknown
- 2015-04-09 CL CL2015000891A patent/CL2015000891A1/es unknown
- 2015-04-17 US US14/689,375 patent/US9227959B2/en active Active
- 2015-04-17 MA MA38012A patent/MA38012B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150629A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| PE20142186A1 (es) | Derivados biciclicos de pirazinona | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| MX373079B (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartílago. | |
| PE20150628A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor mglur5 | |
| PE20080941A1 (es) | Compuestos triciclicos como agonistas del receptor de melatonina | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| EA201300389A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| PH12015502692B1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| PE20090115A1 (es) | Derivados de indol-2-il-piperazin-1-il-metanona | |
| EA201290534A1 (ru) | Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов | |
| CY1120608T1 (el) | Φαρμακευτικως δραστικες ενωσεις | |
| UA114008C2 (xx) | Похідні етинілу як модулятори активності рецептора mglur5 | |
| RU2016111390A (ru) | Неконкурентные антагонисты никотиновых рецепторов | |
| PE20150708A1 (es) | Derivados de ariletinilo | |
| RU2014122338A (ru) | Неконкурентные модуляторы никотиновых рецепторов | |
| MX2017015043A (es) | Derivados de etinilo. | |
| WO2010134846A8 (ru) | Замещенные 8-cульфohил-2,3,4,5-tetpaгидpo-1h-гamma- карболины, лиганды, фармацевтическая композиция, способ их получения и применения | |
| TH137350A (th) | แอริลเมทธิลเบนโซควินาโซลิโนน สารปรับควบคุมอัลโลสเตอริกแบบบวกของ m1 รีเซพเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |